Ignite Creation Date:
2025-12-25 @ 3:38 AM
Ignite Modification Date:
2025-12-26 @ 2:22 AM
Study NCT ID:
NCT06057402
Status:
RECRUITING
Last Update Posted:
2025-12-22
First Post:
2023-09-05
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Sponsor:
Pfizer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-10-03
Start Date Type:
ACTUAL
Primary Completion Date:
2032-02-22
Primary Completion Date Type:
ESTIMATED
Completion Date:
2032-02-22
Completion Date Type:
ESTIMATED
First Submit Date:
2023-09-05
First Submit QC Date:
None
Study First Post Date:
2023-09-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-18
Last Update Post Date:
2025-12-22
Last Update Post Date Type:
ESTIMATED